- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07632027
Bedside Assessment of Right Ventricular Output Lying in Prone Or Supine Position (BAROLO)
The BAROLO Study Bedside Assessment of Right Ventricular Output Lying in Prone Or Supine Position. Hemodynamic Changes Due to Prone Position in Patients After Cardiac Surgery - a Prospective Randomized Controlled Trial Evaluating the Effect of Prone Position on Right Heart Function
Right ventricular failure (RVF) is a common complication to cardiac surgery, which is associated to mortality, kidney failure, stroke, prolonged mechanical ventilation and ICU stay. The right ventricle is particularly vulnerable to an increased afterload. By increasing pulmonary vascular resistance (PVR), atelectasis might mitigate a negative effect on the right ventricle.
Recruitment maneuvers have been shown to resolve atelectasis and improve hemodynamics by increasing cardiac output and lowering PVR. However these maneuvers transiently raise airway pressures, which in turn increases right ventricular afterload, a situation often poorly tolerated by patients with RVF.
Prone position is used in patients with respiratory failure and has been shown to decrease mortality in patients with ARDS. Prone position decreases atelectasis and moves ventilation dorsally. In ARDS it also seems to mediate beneficial hemodynamic effects such as an increase in cardiac output and a decrease in PVR.
The investigators hypothesis is that prone position early after cardiac surgery will increase cardiac output by recruitment of atelectasis and thereby decrease PVR.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Recruitment and consent:
Patients will be screened for participation no later than the day before surgery. Potential participants will be given written and verbal information regarding the study and time to ask questions and consider their participation.
Randomization:
After end of surgery, at baseline in the ICU, patients will be randomly allocated (1:1 ratio) to supine position and prone position. Block randomization with variable block sizes will be performed with sequentially numbered, opaque, sealed envelopes. All performed by Statistiska konsultgruppen. Patient stratification according to cardiac index at end-surgery will be performed to ensure similar allocation of patients with cardiac index <2.2 L/min/m2 in each group. The investigator who enrolls study participants will not have access to the random allocation sequence.
Sample Size:
Based on previous studies regarding cardiac surgery or prone position a power calculation was performed using a two-sample comparison of means, with equally sized independent groups. With an intention to detect a 20% difference in cardiac index in the intervention group and with 80% power, 0.05 α, estimated mean CI 2.6(0.8 SD) in control group, and CI 3.2 in the prone group, calcuation rendered n=70 divided in 2 equally large groups. As patients intermittently require recurring surgery due to i.e. bleeding, some patients will be excluded after inclusion. Based on this and the power analysis 80 patients will be included and randomized to supine position (n=40) and prone position (n=40).
Description of method:
In included patients, anesthesia will be performed with Propofol, Fentanyl and Sevoflurane. As per clinical routine patients will have a central venous catheter, 1-2 arterial catheters, TEE probe and endotracheal tube inserted. Study participants will also get a pulmonary artery catheter (PAC) inserted prior to surgery to facilitate measurement of cardiac output using thermodilution and PVR. Body surface area is calculated using the Mosteller formula.
During surgery, after CPB is weaned, the attending anaesthesiologist is instructed to refrain from additional recruitment maneuvers and a PEEP >8 cmH2O. Unless FiO2 is >80% to maintain adequate oxygenation of the patient or the anaesthesiologist deems it necessary.
When surgery is finished, the patient will be moved to the Thoracic ICU. Ventilation performed with a Maquet Servo-U (Getinge, SE) is set to volume control, tidal volumes of 6 ml/kg IBW with a respiratory rate of 12-18 and PEEP 8 cmH2O. Data collection occurs in all patients in supine position (0). Hereafter the study group is turned to prone while the control group remains in supine position.
60 minutes after proning data is again collected (t1), whereafter a recruitment maneuver is performed by gradually increasing PEEP during 2,5 minutes in 6 steps to 20 cmH2O during. After 30 seconds PEEP is decreased in 6 steps during 2,5 minutes to reach PEEP 8 cmH2O. Data is collected after the recruitment maneuver (t2) and one hour after (t3), adding up to a total of 2 hours and 15 minutes in supine or prone position. The patients in prone position are turned to supine position and the last data collection occurs (t4). In total 5 time points for data collection. Postoperative care will now continue as per routine care. Patients will be extubated as soon as possible according to clinical routine and eventually discharged from the ICU.
Since a recruitment maneuver transiently increases right ventricular afterload there is a possibility not all patients will tolerate the recruitment maneuver as described above. As per clinical practice the level of airway pressures during recruitment will be adjusted when needed to avoid adverse effects.
Discontinuation of the intervention:
In order to minimize harm the following set criteria will be used to discontinue prone position:
- Hemodynamic instability with increased Norepinephrine >0.7mcg/kg/min
- Sustained arrythmia which requires treatment including DC conversion
- Any condition which, in the judgement of the investigator, might increase risk of harm to the patient
Blinding:
After allocation to supine or prone position neither the investigator, nor ordinary ICU personnel, will be blinded due to safety and impracticalities. Patients are blinded due to being under general anaesthesia during randomization until weaning from mechanical ventilation (after the study protocol is completed).
Data collection:
A site investigator will record data using a software developed by Getinge from the respirator to a designated research computer. All other data and variables, mentioned above, will be collected from the participants digital chart and real time monitoring (Philips IntelliVue & BD Hemosphere).
Data management:
Collected data is pseudonymized and stored on a password protected designated research computer. Only authorized study personnel have access to the computer.
Original records, including signed written consent, are kept with strict confidence. These records will be kept in a secure, locked and limited access location at Sahlgrenska Univeristy Hospital during the study and after completion for an additional 10 years. At inclusion each patient is pseudonymized by receiving a participant ID, which is used in all data files.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Viktor Erbring, MD
- Número de teléfono: +46706456664
- Correo electrónico: viktor.erbring@vgregion.se
Copia de seguridad de contactos de estudio
- Nombre: Per Persson, MD, PhD
- Número de teléfono: +46736467042
- Correo electrónico: per.persson@vgregion.se
Ubicaciones de estudio
-
-
-
Gothenburg, Suecia, 41345
- Cardiac Intensive Care Unit
-
Contacto:
- Viktor Erbring, MD
- Número de teléfono: +46706456664
- Correo electrónico: viktor.erbring@vgregion.se
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Scheduled for cardiac surgery using cardiopulmonary bypass
Exclusion Criteria:
- BMI >40
- Emergency surgery
- In need of secondary surgery
- Advanced grown up congenital heart disease
- Pulmonary disease
- Hemodynamic instability with Norepinephrine >0.4mcg/kg/min
- Any condition which, in the judgement of the investigator, might increase the risk to the patient
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Sin intervención: Supine position
Control group.
Will remain in supine position for the whole protocol.
|
|
|
Experimental: Prone position
Will be turned to prone position after baseline data collection (0) and return to supine position before the final data collection (t4).
|
Prone position is applied in the intervention group immediately after randomization, patients will be prone for a total of 2 hours and 15 minutes.
During this time 3 data collection points occur (t1, t2 & t3).
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cardiac Index
Periodo de tiempo: 1 hour after baseline
|
L/min/m2
|
1 hour after baseline
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
PVRi
Periodo de tiempo: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
Difference between and within groups
|
At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
|
Cardiac Index
Periodo de tiempo: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
Difference between and within groups
|
At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
|
PaO2:FiO2
Periodo de tiempo: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
Within and between groups
|
At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
|
Driving Pressure
Periodo de tiempo: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
Plateau Pressure - PEEP
|
At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
|
ICU length of stay
Periodo de tiempo: Perioperative
|
Time from start to end of the ICU visit, measured in days.
|
Perioperative
|
|
Time to extubation
Periodo de tiempo: Perioperative
|
Time from arrival to the ICU until patient's endotracheal tube is removed (extubation).
Measured in hours.
|
Perioperative
|
|
Adverse events
Periodo de tiempo: At any point in time from Baseline to 2 hours and 45 minutes after Baseline.
|
Severity graded: Mild, Moderate & Severe Causality: Due to prone position?
Other reason?
|
At any point in time from Baseline to 2 hours and 45 minutes after Baseline.
|
|
RV pressure
Periodo de tiempo: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
Looking at differences of right ventricular blood pressure between groups at all timepoints
|
At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
|
Vasopressor dose
Periodo de tiempo: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
Difference of actual vasopressor dose within and between groups at all timepoints
|
At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
|
Inotrope dose
Periodo de tiempo: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
Difference of actual inotrope dose between groups at all timepoints
|
At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
|
CVP
Periodo de tiempo: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
Difference in central venous pressure within and between groups at all timepoints
|
At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
|
PAP
Periodo de tiempo: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
Difference in pulmonary artery pressure within and between groups at all timepoints
|
At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
|
PCWP
Periodo de tiempo: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
Difference in pulmonary capillary wedge pressure within and between groups at all timepoints
|
At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
|
Systemic blood pressure
Periodo de tiempo: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
Difference in systemic blood pressure within and between groups at all timepoints
|
At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
|
Heart rate
Periodo de tiempo: 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
Difference in heart rate within and between groups at all timepoints
|
1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
RV contractility during recruitment maneuver
Periodo de tiempo: During recruitment (1 hour after baseline).
|
Measured as dP/dt (mmHg/s).
Maximum upslope of the pressure waveform measured at the RV.
|
During recruitment (1 hour after baseline).
|
|
Physiological dead space
Periodo de tiempo: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
Eventual exploratory outcome.
Analysis of VD/VT using Enghoff-modified Bohr equations.
|
At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
|
Subgroup analysis of Cardiac Index
Periodo de tiempo: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
Patients with perioperative or postoperative diagnosed RVF according to a published standardized definition will be analyzed separately in a subgroup analysis.
|
At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
|
Subgroup analysis of PVRi
Periodo de tiempo: At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
Patients with perioperative or postoperative diagnosed RVF according to a published standardized definition will be analyzed separately in a subgroup analysis.
|
At baseline. 1 hour after baseline. 1 hour 15 minutes after baseline. 2 hours 15 minutes after baseline. 2 hours 45 minutes after baseline.
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 286380
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .